Literature DB >> 27221907

Estimating the Economic Burden of Premature Mortality Caused by Cancer in Iran: 2006-2010.

Behzad Karami-Matin1, Farid Najafi, Satar Rezaei, Ardashir Khosravi, Moslem Soofi.   

Abstract

BACKGROUND: Cancer is currently one of the main public health problems all over the world and its economic burden is substantial both for health systems and for society as a whole.To inform priorities for cancer control, we here estimated years of potential life lost (YPLL) and productivity losses due to cancer-related premature mortality in Iran from 2006 to 2010.
MATERIALS AND METHODS: The number of cancer deaths by sex and age groups for top ten leading cancers in Iran were obtained from the Ministry of Health and Medical Education. To estimate theYPLL and the cost of productivity loss due to cancer-related premature mortality, the life expectancy method and the human capital approach were used, respectively.
RESULTS: There were 138,228 cancer-related deaths in Iran (without Tehran province) of which 76 % (106,954) were attributable to the top 10 ranked cancers. Some 63 % of total cancer-related deaths were of males. The top 10 ranked cancers resulted in 106,766,942 YPLL in total, 64,171,529 (60 %) in males and 42,595,412 (40%) in females. The estimated YPPLL due to top 10 ranked cancers was 58,581,737 during the period studied of which 32,214,524 (54%) was accounted for in males.The total cost of lost productivity caused by premature deaths because of top 10 cancers was 1.68 billion dollars (US$) from 2006 to 2010, ranging from 251 million dollars in 2006 to 283 million dollars in 2010.
CONCLUSIONS: This study showed that the economic burden of premature mortality attributable to cancer is significant for Iranian society. The findings provide useful information about the economic impact of cancer for health system policy/ decision makers and should facilitate planning of preventive intervention and effective resource allocation.

Entities:  

Mesh:

Year:  2016        PMID: 27221907     DOI: 10.7314/apjcp.2016.17.4.2131

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  4 in total

Review 1.  Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention.

Authors:  Zahra Fathi; Nicholas L Syn; Jian-Guo Zhou; Raheleh Roudi
Journal:  J Hum Genet       Date:  2018-04-18       Impact factor: 3.172

2.  Economic Burden of Gastric Cancer: A Case of Iran.

Authors:  Abed Eghdami; Rahim Ostovar; Abdosaleh Jafari; Andrew J Palmer; Najmeh Bordbar; Ramin Ravangard
Journal:  Cancer Control       Date:  2019 Jan-Dec       Impact factor: 3.302

3.  Comment on: "Economic Burden of Thalassemia Major in Iran, 2015".

Authors:  Satar Rezaei; Behzad Karami Matin; Mohammad Hajizadeh
Journal:  J Res Health Sci       Date:  2016

4.  Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.

Authors:  Zahra Fathi; Seyed Ali Javad Mousavi; Raheleh Roudi; Farideh Ghazi
Journal:  PLoS One       Date:  2018-07-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.